Donate

Publication

Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop

Citation:
National Academies of Sciences, Engineering, and Medicine. 2022. Exploring Psychedelics and Entactogens as Treatments for Psychiatric Disorders: Proceedings of a Workshop. Washington, DC: The National Academies Press. https://doi.org/10.17226/26648.
Abstract:
Psychiatric illnesses – such as major depressive disorder, anxiety disorder, substance use disorder, and posttraumatic stress disorder (PTSD) – are widely prevalent and represent a substantial health burden worldwide. Yet, conventional medications for mental illnesses often fail to provide relief to patients’ disruptive and disabling symptoms. Existing and emerging evidence that psychedelics (e.g., LSD and psilocybin) and entactogens (e.g., MDMA) may be useful as tools to alleviate mental illness has sparked a renaissance of interest by investigators, clinicians, drug developers, and patient advocates in recent years. While promising data on therapeutic efficacy has energized research and development, resolving the mechanisms of action will be important for optimizing the efficacy and safety of these medicines. Further, evaluating the effect of psychedelics and entactogens on mood and behavior comes with unique challenges still in need of resolution. These include unresolved questions relating to blinding, placebo and nocebo effects, and the impact of psychosocial contexts.
Published in:
National Academies of Sciences, Engineering, and Medicine
View article

More Publications

August 1, 2023

Journal of Psychopharmacology

Improving Translational Relevance in Preclinical Psychopharmacology (iTRIPP)

View
July 6, 2023

Gerontology and Geriatric Medicine

Caring for Dementia Caregivers: Understanding Caregiver Stress During the COVID-19 Pandemic

View
May 19, 2023

Nature Reviews Neurology

Global synergistic actions to improve brain health for human development

View
April 20, 2023

Nature Mental Health

Machine learning-based identification of a psychotherapy-predictive electroencephalographic signature in PTSD

View
February 21, 2023

Translational Psychiatry

Screening for PTSD and TBI in Veterans using Routine Clinical Laboratory Blood Tests

View
February 13, 2023

Frontiers in Aging Neuroscience

Machine learning within the Parkinson’s progression markers initiative: Review of the current state of affairs

View
View All

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics.

©2023 Cohen Veterans Bioscience |  Privacy Policy | Terms of Use

Newsletter
Donate